{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:15:01Z","timestamp":1761581701810},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.mayocp.2018.01.032","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T10:31:45Z","timestamp":1527157905000},"page":"1026-1033","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"93","author":[{"given":"Aaron S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocp.2018.01.032_bib1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/jamainternmed.2015.2857","article-title":"Faster drug approvals are not always better and can be worse","volume":"175","author":"Redberg","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.mayocp.2018.01.032_bib2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","article-title":"End points and United States Food and Drug Administration approval of oncology drugs","volume":"21","author":"Johnson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2018.01.032_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1467-9566.2010.01310.x","article-title":"Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation","volume":"33","author":"Davis","year":"2011","journal-title":"Sociol Health Illn"},{"issue":"34","key":"10.1016\/j.mayocp.2018.01.032_bib4","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2018.01.032_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mayocp.2018.01.032_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2017.01.004","article-title":"Immune checkpoint inhibition in malignant mesothelioma: does it have a future?","volume":"105","author":"Mansfield","year":"2017","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.mayocp.2018.01.032_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.032_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.032_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2018.01.032_bib10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2018.01.032_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.032_bib12","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0169-5002(05)80924-9","article-title":"P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model","volume":"49","author":"Symanowski","year":"2005","journal-title":"Lung Cancer"},{"issue":"23","key":"10.1016\/j.mayocp.2018.01.032_bib13","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.mayocp.2018.01.032_bib14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"Hazarika","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.032_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.2016-0121","article-title":"Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials","volume":"22","author":"Wang","year":"2017","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.mayocp.2018.01.032_bib16","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","article-title":"Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma","volume":"48","author":"Blayney","year":"2012","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.mayocp.2018.01.032_bib17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.ejca.2014.07.020","volume":"50","author":"Hasan","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.mayocp.2018.01.032_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2016.09.003","article-title":"Imaging in pleural mesothelioma: a review of the 13th International Conference of the International Mesothelioma Interest Group","volume":"101","author":"Armato","year":"2016","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2018.01.032_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American Multicenter Volumetric CT Study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.mayocp.2018.01.032_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejrad.2016.11.009","article-title":"Metabolic response assessment with 18F-FDG-PET\/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma","volume":"86","author":"Kanemura","year":"2017","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.01.032_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A\u00a0multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"10026","key":"10.1016\/j.mayocp.2018.01.032_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2018.01.032_bib23","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2018.01.032_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.01.032_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2018.01.032_bib26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaoncol.2016.6135","article-title":"Is there room for second-line treatment of pleural malignant mesothelioma?","volume":"3","author":"Addeo","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618301861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618301861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T03:17:39Z","timestamp":1661311059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619618301861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0025619618301861"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.01.032","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}